Overview
Nuvelo is focused on clinical development in the areas of acute cardiovascular disease, cancer and other debilitating medical conditions.
Nuvelo’s pipeline includes: NU172, a direct thrombin inhibitor that has completed Phase 1 clinical development, for use during medical and surgical procedures which require an anticoagulant; and Phase 1 clinical candidate NU206 for potential treatment of gastrointestinal (GI) injury, inflammatory bowel disease, bone disease, and wound-healing.